Bio-Rad Laboratories (BIO) 138.69 $BIO Bio-Rad Unveils

New Post Public Reply Private Reply Replies (0) Message Board

Jun 25, 2016 at 5:17 PM

Bio-Rad Laboratories (BIO) 138.69 $BIO

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 138.69 (-3.70)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 138.69 (-3.70)

Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 138.69 (-3.70), ILMN: 138.91 (-7.68), BIO.B: 140.58 (unch)

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 9.40 (-0.69), BIO: 138.69 (-3.70), ILMN: 138.91 (-7.68), EXAC: 25.61 (-0.69)

Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 146.59 (-8.76), BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 138.69 (-3.70), ILMN: 138.91 (-7.68)

Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

FDA Okays Bio-Rad D-100 for HbA1c (Diabetes) Testing
Zacks Equity Research - Zacks Investment Research - Mon Dec 21, 1:25PM CST
Bio-Rad's (BIO) D-100 System delivers rapid high-quality HbA1c testing, without sacrificing the ability to detect hemoglobin variants that can interfere with the interpretation of test results.
CAPR: 4.18 (-0.20), ICUI: 106.49 (-1.64), INSY: 12.62 (-0.45), BIO: 138.69 (-3.70)

10X Genomics Founders Prevail in Dispute with Bio-Rad
BusinessWire - Mon Dec 21, 6:00AM CST
10X Genomics, Inc., today announced that its founders and executive officers, Drs. Serge Saxonov, Benjamin Hindson and Kevin Ness, have unequivocally prevailed in an arbitrated dispute brought against them by Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 138.69 (-3.70)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
BIO: 138.69 (-3.70), BIO.B: 140.58 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SOTERIA Launches Cancer Hunt™ for Military Patients

Breaking the Barriers for Our Military's Cancer Fight Diving into the world of precision medicine, SOTERIA Precision Medicine Foundation has sparked a revolution with Cancer Hunt™. It's staggering to think about the piles of bureaucracy and insurance red tape that often stand between cancer patients and life-saving care. Especially when those patients are veterans or...

Barco Brings HDR Cinema Home with Kinepolis Kortrijk

A New Chapter in Cinema Projection Ah, Belgium, the land of waffles and apparently, cutting-edge cinema tech. That's right, Barco is bringing their HDR by Barco system to its own backyard in Kortrijk, teaming up with Kinepolis to shake things up. It's not just any expansion—it's a homecoming of sorts. The company's laser cinema magic has already made face time in the...

Hanwha's Big Bet: Tokenizing Real-World Assets with Chainlink

Hanwha and Chainlink: A Game Changer in Tokenization What do Hanwha Investment & Securities, a heavyweight in Korea's finance scene, and Chainlink, the wizard of onchain finance, think they're up to? They're buddies now, locked and loaded, to tokenize real-world assets (RWAs). They're not just shaking hands; they're aiming to jiggle the global finance bedrock....

Banco Santander's Troubles: Legal Heat on SAN

By Caleb Price Updated Oct 29, 2026 Category News Views 129

Brazilian Turbulence Shakes Banco Santander Imagine getting hit twice in a single week, once by a surprise election result and again by numbers that don't add up. That's the gut-wrenching scenario Banco Santander's (NYSE: SAN) investors are facing. After Brazil's unexpected election outcome, investor jitters translated into a 3.7% drop on October 26, 2026. Not two days...

JAS Hits Top 1% in EcoVadis Sustainability Rankings

A Platinum Performance in EcoVadis Ratings JAS Worldwide, hustling around in the logistics and supply chain sector, just nailed a spot in the much-coveted top 1% bracket for sustainability according to EcoVadis. We’re talking about a company that’s not only steering the mammoth ships of logistics but now it’s also wearing sustainability like a crown. This...

Kuvings Unveils Hands-Free Juicer for Healthy Living

A Fresh Squeeze in the Juice World If you've ever wanted something that makes that morning juice without you running a marathon in your own kitchen, Kuvings might just have the answer with their new AUTO10 SQUARE™ Plus. Announced on October 30, 2026, this isn't just another fancy named gadget—it actually shakes things up with a hands-free design that’s tailored for...

Birth Injury Lawsuit Secures $19.1M Award in Michigan

Legal Triumph for Sokolove's Birth Injury Case There are days when you see a win in the courtroom and think maybe, just maybe, justice ain't just a fairytale. Today, that thought knocks heavier with news rolling out of Michigan—an astronomical $19.1 million awarded to a family by a federal judge after a botched birth led to lifelong medical issues. You've got Sokolove...

Geolava, Vaidio, Sensoneo Triumph in Texas Pitch Contest

North Texas Lights the Innovation Torch Big moves are happening in North Texas, with a pitch competition that's more than just smoke and mirrors. We're talking about an arena where regional challenges meet cutting-edge solutions, and out of a global mix, Geolava, Vaidio, and Sensoneo snagged the 2026 North Texas Connected Innovation Pitch Contest crown. It's high stakes...

Cohere's CAD $7 Billion Raise Signals AI Power Shift

Changing the Game: Cohere's Massive Series E Raise There's a seismic shift happening up north, and it’s not the aurora borealis. Cohere just announced the initial close of a staggering CAD $7 billion Series E funding round, eyeing a CAD $35.7 billion valuation. If it pans out, it’d be the kind of cash grab that's never been seen in Canadian tech history. Why This...

ACTEC Welcomes 55 New Fellows: A Closer Look

By Dylan Bailey Updated Oct 29, 2026 Category News Views 115

Coffee's brewing hot, and so are the stakes at ACTEC, where 55 new Fellows just got the nod. The American College of Trust and Estate Counsel isn't your average club. They've been at this game since 1949, bringing together the finest minds in trusts and estates. But what does this newest batch bring to the table, and why should investors take a moment to notice? A Diverse...